The aim of this study was to examine hormone therapy (HT) users' experiences, perceptions and information sources in 2009.
Questionnaire survey was conducted in 2009 among women using HT. The questionnaire (n=500) was distributed from pharmacies across Finland. The response rate was 58% (n=281).
The survey measured self-reported benefits and adverse reactions, fears and information sources.
The number of systemic HT users reporting fears was 50% (n=99). The most common fear was breast cancer (27%). Systemic HT users who had considered discontinuation of HT or had temporarily discontinued HT experienced fears more often than other respondents (p